[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603452":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":24,"responsibleParty":41,"collaborators":45,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Early-onset pancreatic neuroendocrine tumors group",null,"This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.",{"label":13,"type":10,"description":14,"interventionNames":10},"Late-onset pancreatic neuroendocrine tumors group","This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Hanxiang Zhan, MD. PhD.","CONTACT","+86 18560085156","zhanhanxiang@hotmail.com",{"name":22,"role":18,"phone":10,"phoneExt":10,"email":23},"Changhao Gao, MMed","gaochanghao44@gmail.com",[25],{"facility":5,"status":10,"city":26,"state":27,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Jinan","Shandong","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.99722,36.66833,{"lat":34,"lon":33},[37],{"name":38,"role":18,"phone":39,"phoneExt":10,"email":40},"Xiaoyang Chen, PhD","+86 185 6008 6888","qlyykyll@163.com",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hanxiang Zhan","Chief Physician, Department of Pancreatic Surgery",[46,48,50],{"name":47,"class":6},"China-Japan Friendship Hospital",{"name":49,"class":6},"The Affiliated Hospital of Qingdao University",{"name":51,"class":6},"Qianfoshan Hospital","100603452","risk-factors-prognosis-clinicopathological-and-metabolic-characteristics-of-eo--vs-lo-pannets-100603452",false,"NCT07136701","Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs","Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study","Inclusion Criteria:\n\n* 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.\n\nExclusion Criteria:\n\n* Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.","ALL","18 Years","85 Years",{"count":63,"type":64},600,"ESTIMATED","OBSERVATIONAL","The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).\n\nThe main questions it aims to answer are:\n\nAre there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.\n\nParticipants will:\n\nProvide retrospective clinical, pathological, and metabolic data from hospital records.\n\nHave survival and recurrence outcomes assessed through follow-up data review.",[68],"Pancreatic Neuroendocine Neoplasms (pNETs)",[70],"EO-PanNET","NOT_YET_RECRUITING","2025-08-21",{"date":74,"type":75},"2025-08-22","ACTUAL",{"date":77,"type":64},"2025-08-31",{"date":79,"type":64},"2027-07-31",{"name":5,"class":6},1]